UNSPSC 51362302: Zolpidem

This classification denotes a sedative and hypnotic with the molecular formula C19H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7K383OQI23, chemically known as n,n,6-trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide but generally known as zolpidem, which bears US NIH Compound Identifier 5732. European Medicines Agency schedules Zolpidem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00183MIG.

UNSPSC 51362302 Zolpidem is a Commodity code that in recent state and local practice encompasses pharmaceutical procurement across a broader spectrum than the specific drug name suggests — state and local health agencies are sourcing generic multi-source pharmaceuticals, over-the-counter products, and opioid-antagonist medications (naloxone) through competitive procurement vehicles designed to serve institutional and community health needs. The issuing bodies include state health and human services departments, county health offices, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Work being solicited ranges from manufacturer agreements with standardized wholesaler channels to direct-to-manufacturer prescription initiatives and tactical procurements for specific public health interventions such as naloxone distribution for overdose response.

Recent activity spans Texas, Minnesota, Oregon, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring manufacturers to work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct relationships between the state's pharmacy benefit program and manufacturers. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, for procurement of 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida.